Test-and-treat in los angeles: A mathematical model of the effects of test-and-treat for the population of men who have sex with men in Los Angeles County

Neeraj Sood, Zachary Wagner, Amber Jaycocks, Emmanuel Drabo, Raffaele Vardavas

Research output: Contribution to journalArticle

Abstract

Background. There is evidence to suggest that antiretroviral therapy (ART) and testing for human immunodeficiency virus (HIV) reduce the probability of transmission of HIV. This has led health officials across the United States to take steps toward a test-and-treat policy. However, the extent of the benefits generated by test-and-treat is debatable, and there are concerns, such as increased multidrug resistance (MDR), that remain unaddressed.Methods. We developed a deterministic epidemiologic model to simulate the HIV/AIDS epidemic for men who have sex with men (MSM) in Los Angeles County (LAC). We calibrated the model to match the HIV surveillance data from LAC across a 10-year period, starting in 2000. We then modified our model to simulate the test-and-treat policy and compared epidemiologic outcomes under the test-and-treat scenario to the status quo scenario over the years 2012-2023. Outcome measures included new infections, deaths, new AIDS cases, and MDR.Results. Relative to the status quo, the test-and-treat model resulted in a 34% reduction in new infections, 19% reduction in deaths, and 39% reduction in new AIDS cases by 2023. However, these results are counterbalanced by a near doubling of the prevalence of MDR (9.06% compared to 4.79%) in 2023. We also found that the effects of increasing testing and treatment were not complementary.Conclusions. Although test-and-treat generates substantial benefits, it will not eliminate the epidemic for MSM in LAC. Moreover, these benefits are counterbalanced by large increases in MDR.

Original languageEnglish (US)
Pages (from-to)1789-1796
Number of pages8
JournalClinical Infectious Diseases
Volume56
Issue number12
DOIs
StatePublished - Jun 15 2013
Externally publishedYes

Fingerprint

Los Angeles
Multiple Drug Resistance
Theoretical Models
HIV
Acquired Immunodeficiency Syndrome
Population
Infection
Outcome Assessment (Health Care)
Health
Therapeutics

Keywords

  • antiretroviral therapy
  • drug resistance
  • HIV/AIDS
  • mathematical model
  • test and treat

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)

Cite this

Test-and-treat in los angeles : A mathematical model of the effects of test-and-treat for the population of men who have sex with men in Los Angeles County. / Sood, Neeraj; Wagner, Zachary; Jaycocks, Amber; Drabo, Emmanuel; Vardavas, Raffaele.

In: Clinical Infectious Diseases, Vol. 56, No. 12, 15.06.2013, p. 1789-1796.

Research output: Contribution to journalArticle

@article{db770ddea13b44499f0b90817bee7ebc,
title = "Test-and-treat in los angeles: A mathematical model of the effects of test-and-treat for the population of men who have sex with men in Los Angeles County",
abstract = "Background. There is evidence to suggest that antiretroviral therapy (ART) and testing for human immunodeficiency virus (HIV) reduce the probability of transmission of HIV. This has led health officials across the United States to take steps toward a test-and-treat policy. However, the extent of the benefits generated by test-and-treat is debatable, and there are concerns, such as increased multidrug resistance (MDR), that remain unaddressed.Methods. We developed a deterministic epidemiologic model to simulate the HIV/AIDS epidemic for men who have sex with men (MSM) in Los Angeles County (LAC). We calibrated the model to match the HIV surveillance data from LAC across a 10-year period, starting in 2000. We then modified our model to simulate the test-and-treat policy and compared epidemiologic outcomes under the test-and-treat scenario to the status quo scenario over the years 2012-2023. Outcome measures included new infections, deaths, new AIDS cases, and MDR.Results. Relative to the status quo, the test-and-treat model resulted in a 34{\%} reduction in new infections, 19{\%} reduction in deaths, and 39{\%} reduction in new AIDS cases by 2023. However, these results are counterbalanced by a near doubling of the prevalence of MDR (9.06{\%} compared to 4.79{\%}) in 2023. We also found that the effects of increasing testing and treatment were not complementary.Conclusions. Although test-and-treat generates substantial benefits, it will not eliminate the epidemic for MSM in LAC. Moreover, these benefits are counterbalanced by large increases in MDR.",
keywords = "antiretroviral therapy, drug resistance, HIV/AIDS, mathematical model, test and treat",
author = "Neeraj Sood and Zachary Wagner and Amber Jaycocks and Emmanuel Drabo and Raffaele Vardavas",
year = "2013",
month = "6",
day = "15",
doi = "10.1093/cid/cit158",
language = "English (US)",
volume = "56",
pages = "1789--1796",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Test-and-treat in los angeles

T2 - A mathematical model of the effects of test-and-treat for the population of men who have sex with men in Los Angeles County

AU - Sood, Neeraj

AU - Wagner, Zachary

AU - Jaycocks, Amber

AU - Drabo, Emmanuel

AU - Vardavas, Raffaele

PY - 2013/6/15

Y1 - 2013/6/15

N2 - Background. There is evidence to suggest that antiretroviral therapy (ART) and testing for human immunodeficiency virus (HIV) reduce the probability of transmission of HIV. This has led health officials across the United States to take steps toward a test-and-treat policy. However, the extent of the benefits generated by test-and-treat is debatable, and there are concerns, such as increased multidrug resistance (MDR), that remain unaddressed.Methods. We developed a deterministic epidemiologic model to simulate the HIV/AIDS epidemic for men who have sex with men (MSM) in Los Angeles County (LAC). We calibrated the model to match the HIV surveillance data from LAC across a 10-year period, starting in 2000. We then modified our model to simulate the test-and-treat policy and compared epidemiologic outcomes under the test-and-treat scenario to the status quo scenario over the years 2012-2023. Outcome measures included new infections, deaths, new AIDS cases, and MDR.Results. Relative to the status quo, the test-and-treat model resulted in a 34% reduction in new infections, 19% reduction in deaths, and 39% reduction in new AIDS cases by 2023. However, these results are counterbalanced by a near doubling of the prevalence of MDR (9.06% compared to 4.79%) in 2023. We also found that the effects of increasing testing and treatment were not complementary.Conclusions. Although test-and-treat generates substantial benefits, it will not eliminate the epidemic for MSM in LAC. Moreover, these benefits are counterbalanced by large increases in MDR.

AB - Background. There is evidence to suggest that antiretroviral therapy (ART) and testing for human immunodeficiency virus (HIV) reduce the probability of transmission of HIV. This has led health officials across the United States to take steps toward a test-and-treat policy. However, the extent of the benefits generated by test-and-treat is debatable, and there are concerns, such as increased multidrug resistance (MDR), that remain unaddressed.Methods. We developed a deterministic epidemiologic model to simulate the HIV/AIDS epidemic for men who have sex with men (MSM) in Los Angeles County (LAC). We calibrated the model to match the HIV surveillance data from LAC across a 10-year period, starting in 2000. We then modified our model to simulate the test-and-treat policy and compared epidemiologic outcomes under the test-and-treat scenario to the status quo scenario over the years 2012-2023. Outcome measures included new infections, deaths, new AIDS cases, and MDR.Results. Relative to the status quo, the test-and-treat model resulted in a 34% reduction in new infections, 19% reduction in deaths, and 39% reduction in new AIDS cases by 2023. However, these results are counterbalanced by a near doubling of the prevalence of MDR (9.06% compared to 4.79%) in 2023. We also found that the effects of increasing testing and treatment were not complementary.Conclusions. Although test-and-treat generates substantial benefits, it will not eliminate the epidemic for MSM in LAC. Moreover, these benefits are counterbalanced by large increases in MDR.

KW - antiretroviral therapy

KW - drug resistance

KW - HIV/AIDS

KW - mathematical model

KW - test and treat

UR - http://www.scopus.com/inward/record.url?scp=84878337526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878337526&partnerID=8YFLogxK

U2 - 10.1093/cid/cit158

DO - 10.1093/cid/cit158

M3 - Article

C2 - 23487387

AN - SCOPUS:84878337526

VL - 56

SP - 1789

EP - 1796

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 12

ER -